Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia

dc.contributor.authorCappellini, Maria Teresa
dc.contributor.authorPorter, John B.
dc.contributor.authorMusallam, Khaled M.
dc.contributor.authorKattamis, Antonis C.
dc.contributor.authorViprakasit, Vip
dc.contributor.authorGalanello, Renzo
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:47:56Z
dc.date.available2025-01-24T11:47:56Z
dc.date.issued2016
dc.description.abstractBACKGROUND: Patients with non-transfusion-dependent thalassemia (NTDT) present with a spectrum of disease severities. Since there are multiple pathophysiologies in such patients, tailoring treatment remains essential. Therefore, one simple, reliable tool would be beneficial to assess disease severity and tailor therapy, particularly for internal medicine specialists who may treat a variety of NTDT patients with a multitude of complications. This would allow for standardization of assessments leading to timely interventions and prevention of complications. METHODS: A working group of NTDT experts was formed to develop a new disease severity scoring system for adult and pediatric patients with NTDT, based on parameters considered to be most pertinent in defining disease severity. RESULTS: 20 parameters were selected for inclusion in the disease severity scoring system. An additional six parameters, largely related to growth and development, were selected specifically for pediatric patients (</= 16 years of age). Consensus of expert opinion was used to establish the selected methods of assessment for each parameter, based on feasibility and availability of technology, cost containment, and avoidance of patient risk. CONCLUSION: We propose that this new disease severity scoring system for adult and pediatric NTDT patients could be developed into a practical tool for widespread clinical use.
dc.identifier.doihttps://doi.org/10.1016/j.ejim.2015.10.003
dc.identifier.eid2-s2.0-84953282116
dc.identifier.pmid26545830
dc.identifier.urihttp://hdl.handle.net/10938/30778
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofEuropean Journal of Internal Medicine
dc.sourceMedline
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAlanine transaminase/blood
dc.subjectArrhythmias, cardiac/epidemiology
dc.subjectBilirubin/blood
dc.subjectBone diseases, metabolic/epidemiology
dc.subjectChild
dc.subjectCholecystectomy
dc.subjectCholecystitis/epidemiology
dc.subjectCholelithiasis/epidemiology
dc.subjectComorbidity
dc.subjectHeart failure/epidemiology
dc.subjectHemoglobins/metabolism
dc.subjectHepatitis b/epidemiology
dc.subjectHepatitis c/epidemiology
dc.subjectHumans
dc.subjectHypertension, pulmonary/epidemiology
dc.subjectIron/blood
dc.subjectLeg ulcer/epidemiology
dc.subjectLiver cirrhosis/epidemiology
dc.subjectOsteoporosis/epidemiology
dc.subjectPlatelet count
dc.subjectSeverity of illness index
dc.subjectSplenomegaly/epidemiology
dc.subjectStroke volume
dc.subjectThrombosis/epidemiology
dc.subjectBeta-thalassemia/blood/epidemiology
dc.subjectDisease severity
dc.subjectNon-transfusion-dependent thalassemia
dc.subjectScoring
dc.titleDevelopment of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia
dc.typeArticle

Files